DANVERS, Mass. (February 24, 2004) – ABIOMED, Inc. (NASDAQ: ABMD) today announced the election of David Gottlieb to the Company's Board of Directors. Mr. Gottlieb comes to ABIOMED having completed more than $45 billion in corporate banking, investment banking and strategic advisory transactions such as mergers and acquisitions in the medical technology, biotechnology and health care services fields. His acceptance to join ABIOMED's Board brings the number of external Directors to seven out of a total of eight Directors.

"David Gottlieb is one of the country's premier strategists for medical technology and life science companies," said Dr. David M. Lederman, Chairman and Chief Executive Officer of ABIOMED. "We are honored that he will be joining us and delighted that we will have the benefit of his strategic insight and financing experience as we continue on our path of commercial growth."

"I am pleased to be working with a company with such an important mission in addressing the needs of underserved patient populations," commented Mr. Gottlieb. "In addition, I have great regard for the professionalism and integrity of ABIOMED's management team, and I am impressed by the level of commitment I see from a highly reputable and experienced Board of Directors. I look forward to helping ABIOMED achieve its mission to address critical market needs with a full spectrum of heart assist and replacement technologies."

Most recently, Mr. Gottlieb served as Global Head of Medical Technology Corporate and Investment Banking for Banc of America Securities LLC. In this role, he was responsible for the sector team covering nearly 300 companies globally in the medical device and hospital supply industry as well as the life science tools, in-vitro diagnostics and diagnostic imaging industries. Previously, he held a number of positions overseeing investment banking for life science companies, including at UBS Investment Bank and Kidder, Peabody & Co. Incorporated.

Mr. Gottlieb holds an MBA from Columbia Business School and a BA from Connecticut College.

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced “AB’-EE-O-MED”) is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. ABIOMED currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company’s AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial.

###

Media Contact:
Andrea tenBroek
Communications Specialist
(978) 646-1419
mediarelations@abiomed.com

Investor Relations Contact:
Edward E. Berger, Ph.D.
Vice President for Policy, Reimbursement and External Relations
(978) 646-1411
ir@abiomed.com